Annual SSc prevalence (2003–2008).
| Year | Annual SSc Prevalence (per 100,000 individuals) | 95% CI |
|---|---|---|
| Base-case analysis | ||
| 2003 | 13.5 | 12.4–14.5 |
| 2004 | 13.7 | 12.7–14.7 |
| 2005 | 13.6 | 12.7–14.6 |
| 2006 | 15.6 | 14.6–16.6 |
| 2007 | 16.2 | 15.1–17.2 |
| 2008 | 18.4 | 17.3–19.5 |
| Sensitivity analysis* | ||
| 2003 | 11.2 | 10.2–12.1 |
| 2004 | 11.5 | 10.6–12.4 |
| 2005 | 11.2 | 10.3–12.1 |
| 2006 | 13.2 | 12.3–14.1 |
| 2007 | 13.8 | 12.9–14.8 |
| 2008 | 16.0 | 14.9–17.0 |
↵* Inclusion required evidence of specialist visit (rheumatologist, dermatologist, or nephrologist) on or within a year following a prevalence date (a prevalence date was any service date that satisfied all inclusion criteria for the prevalence cohort, and specialist visit was recorded at every nonmissing prevalence date between 2003 and 2008).